CLL NGS by siParadigm includes driver genes known to be recurrently mutated in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), genes involved in B-cell receptor signaling, and genes associated with a specific class of targeted therapy.

This panel is useful in diagnosis of CLL/SLL, in risk stratification/prognosis, and in prediction of response or resistance to select therapies. Certain mutations in specific genes in this panel are associated with:

- Poor outcome
- Shorter overall and progression-free survival
- Resistance to fludarabine, ibrutinib, radiation therapy, or rituximab
- Increased likelihood of Richter transformation
- Response to targeted therapy

CLL Panel-Genes (17) and Targeted Regions		
ATM (exons 2-63)	*BTK* (exons 14-16)	*BIRC3* (exons 6-8)
CARD11 (exons 2-8)	*CD79B* (exons 4-5)	*DDX3X* (exons 7-9, 11, 14)
FBXW7 (exons 6-9)	*MAPK1* (exon 7)	*MYD88* (exons 3-5)
NOTCH1 (hotspots)	*PIK3CA* (hotspots)	*PIK3CD* (hotspots)
PTEN (hotspots)	*PTPN6* (hotspots)	*SF3B1* (hotspots)
TP53 (exons 2-11)	*XPO* (exons 12-13, 15)	